KATLYN LANGEBRAKE: Open Payments
NPI 1982314340 · JASPER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,245 in 65 payments from 12 companies in 2025. Trend: 2023 $420 · 2024 $1,087 · 2025 $1,245
Food & beverage: $1,245
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $487 |
| Janssen Biotech, Inc. | 8 | $266 |
| Madrigal Pharmaceuticals | 6 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Ardelyx, Inc. | 4 | $65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $58 |
| Intercept Pharmaceuticals, Inc. | 2 | $34 |
| QOL Medical, LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, LINZESS, ENTYVIO, IBSRELA, XIFAXAN, OCALIVA.
Industry payments across IN — which companies pay providers there.
